Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies

Dateline City: KENILWORTH, N.J. & BERKELEY, Calif. Studies to Evaluate the Combination of Dynavax’s SD-101 with Two Immunotherapies from Merck’s Pipeline, KEYTRUDA® (pembrolizumab) and MK-1966 Collaboration Includes First-in-human Study for MK-1966, a New Investigational Anti-interleukin-10 (anti-IL-10) Immunomodulator from Merck’s Rapidly Growing Immuno-oncology Pipeline KENILWORTH, N.J. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orMerck Investor Relations:Justin Holko, 908-740-1879orDynavax Investor/Media Relations:Michael Ostrach, 510-665-7257 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news